Efficacy and safety of low dose-steroid treatment for acute exacerbation of idiopathic interstitial pneumonia

Phase 2

Recruiting

• Conditions: Acute exacerbation of idiopathic interstitial pneumonia

• Registration Number: JPRN-jRCT1061220085
• Lead Sponsor: Takeshi Masuda

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-01-22
• Last Update Posted: 1 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

1. Over 18 years old
2. Witten informed consent
3. Patients with acute exacerbation of idiopathic interstitial pneumonia
4. Patients who do not require intubation or non- invasive ventilation
5. No progression of interstitial pneumonia on the 3rd day of steroid pulse therapy (methylprednisolone 1 g for 3 days)

Exclusion Criteria

1. Patients receiving immunosuppressants
2. Patients with interstitial pneumonia other than idiopathic interstitial pneumonia (e.g. collagen vascular disease, pneumoconiosis, drug-induced pneumonia, radiation pneumonitis, sarcoidosis, hypersensitivity pneumonia)
3. Patients with serum creatinine over 1.5 times the upper limit of normal
4. Patients with serious complications
5. Patients who lack the ability to consent
6. Patients with hypersensitivity to prednisolone
7. Patients receiving desmopressin acetate hydrate
8. Pregnancy
9. Patients judged by the principal investigator or co-investigator to be inappropriate for this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment success rate at day 18 from start of study treatment

Secondary Outcome Measures

Name	Time	Method
1. Ratio of cases that meet the following conditions on day 18 of study treatment compared to the end date of steroid pulse therapy<br>- Decrease in PaO2/FiO2 ratio due to interstitial pneumonia<br>- Worsen of chest X-ray or CT findings due to interstitial pneumonia<br>- Increase in the level of CRP <br>- Increase in the level of KL-6<br>- Worsen of mMRC scale<br>2. Duration until discharge after start of study treatment<br>3. Cumulative recurrence rate of acute exacerbations at 60 days from the start of study treatment<br>4. Survival rate at 60 days from start of study treatment<br>5. Adverse events during the study treatment <br>6. Adverse events related to steroids at 60 days